A multicenter, Randomized, Double-blind Study of tolerance, pharmacokinetics, and antiviral activity of Yimitasvir Phosphate capsule in Treatment-Nave Subjects with Chronic Genotype 1 HCV Infection

Trial Profile

A multicenter, Randomized, Double-blind Study of tolerance, pharmacokinetics, and antiviral activity of Yimitasvir Phosphate capsule in Treatment-Nave Subjects with Chronic Genotype 1 HCV Infection

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Yimitasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Oct 2016 Status changed from recruiting to completed, as reported by a TaiGen Biotechnology media release.
    • 02 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top